NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability